ERBB2 and breast cancer: In particular, the evidence of intratumor enrichment of HER2/CD36/CD44v6-coexpressing stem-like cells in pre-neoadjuvant treatment biopsies from HER2 + BC patients who did not achieve pCR compared with those who achieved pCR clearly underscores the crucial role played by CD36 in HER2 inhibitor resistance in the HER2 + BC oncotype and emphasizes how CD36 inhibition influences parameters such as invasiveness, relapse, metastatic potential and stemness [14].